RxDoctor Payments DataLook up a doctor →

James Schaupp, DO

Family Medicine · Reno, NVNPI 1770679706

Payments from drug & device makers

$7,926in general payments, 2019–2025

Across 448 payments — averaging $17.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Astellas Pharma US Inc$791
  • GSK$741
  • AstraZeneca$730
  • Pfizer$579
  • Amarin Pharma, Inc.$515
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$7,57896%
  • Education$3484%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,926 in reported general payments places this provider in the 90th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$51,546
Medicare patients
233
Services billed
603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$36,345
EliquisApixaban30$33,298
JardianceEmpagliflozin19$26,772
XareltoRivaroxaban19$22,574
Bydureon BciseExenatide Microspheres14$21,662
FarxigaDapagliflozin Propanediol11$15,265
TradjentaLinagliptin13$14,781
VascepaIcosapent Ethyl13$12,160
Atorvastatin Calcium209$3,412
Wixela InhubFluticasone Propion/Salmeterol11$3,066
Rosuvastatin Calcium101$2,257
Lisinopril219$1,828
Ezetimibe47$1,643
Levothyroxine Sodium111$1,485
Amlodipine Besylate167$1,469

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$392$41,55332 claims
GSKTrelegy Ellipta$741$36,34526 claims
PfizerEliquis$579$33,29830 claims
Johnson & JohnsonXarelto$114$22,57419 claims
AstraZenecaFarxiga$730$15,26511 claims
AbbVieSynthroid$1,049$87813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 902 family medicine providers in Nevada.

Other family medicine in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →